SCHEMBL6109543

SCHEMBL6109543

Cc1ccc(NC(=O)c2cc(Cl)ccc2N(C)C2CCN(C3CCSCC3)CC2)nc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 8/20 0.45
▸ POLB P06746 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.42
▸ RAB9A P51151 4/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ NR3C1 P04150 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6107211 0.95 F10 (0.44) F10POLBALDH1A1RAB9ANPC1
SCHEMBL6108875 0.94 F10 (0.47) F10USP30
SCHEMBL6107548 0.92 F10 (0.47) F10POLBALDH1A1RAB9ANPC1
SCHEMBL6109065 0.91 F10 (0.47) F10POLBALDH1A1RAB9ANPC1
SCHEMBL6108914 0.91 F10 (0.47) F10POLBALDH1A1RAB9ANPC1
SCHEMBL6107625 0.90 POLB (0.46) F10POLBALDH1A1RAB9ANPC1
SCHEMBL7363828 0.89 POLB (0.44) F10POLBALDH1A1RAB9ANPC1
SCHEMBL6112518 0.89 F10 (0.45) F10POLBALDH1A1RAB9ANPC1
SCHEMBL6108579 0.89 F10 (0.45) F10USP30
SCHEMBL6108521 0.86 F10 (0.44) F10POLBALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129245-B2 Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots ELI LILLY AND COMPANY (US) 2006-10-31 — — US disclosed
US-20050282862-A1 Aromatic amides BEIGHT DOUGLAS W 2005-12-22 — — US disclosed
EP-1140903-B1 AROMATIC AMIDES LILLY CO ELI (US) 2004-08-04 — — EP disclosed
US-6759414-B2 ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS ELI LILLY AND COMPANY 2004-07-06 — — US disclosed
US-20040029874-A1 Aromatic amides BEIGHT DOUGLAS WADE (US) 2004-02-12 — — US disclosed
US-6635657-B1 Pyridine derivatives; anticoagulants ELI LILLY AND COMPANY 2003-10-21 — — US disclosed
EP-1140903-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
WO-2000039118-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029874-A1 Aromatic amides F11, F12, F5 F10 12/4885POLB 4161/4885ALDH1A1 1238/4885
US-20050282862-A1 Aromatic amides F11, F12, F5 F10 12/4885POLB 4161/4885ALDH1A1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback